Business Context and Reporting Period
This Form 8-K was filed by Xenomics, Inc. (not Cardiff Oncology, Inc.) on September 9, 2004, reporting events occurring on September 3, 2004. The filing details the entry into a material definitive agreement regarding executive leadership.
Key Financial Metrics
The filing does not provide standard financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on executive compensation terms.
- Base Salary: $215,000 annually.
- One-time Fee: $10,000 consulting fee for a presentation in Germany.
- Stock Options: 1,050,000 incentive stock options at an exercise price of $2.25 per share.
- Performance Bonus: $500,000 cash bonus contingent on a sale of the company exceeding $9.25 per share.
Material Changes
The primary material change is the appointment of Dr. V. Randy White as Chief Executive Officer, effective September 3, 2004. This appointment is governed by a three-year Letter Agreement. A definitive employment agreement is currently being negotiated to replace this Letter Agreement.
Outlook, Risks, and Unusual Items
Management Commentary: The company issued a press release on September 7, 2004, announcing the appointment. The Letter Agreement includes specific vesting schedules and performance triggers.
Unusual Items/Contingencies:
- Accelerated Vesting: All unvested options will immediately vest if the company is sold for consideration exceeding $9.25 per share.
- Stock Price Trigger: All unvested options will immediately vest if the common stock price exceeds $9.25 for 60 consecutive trading days.
- Restrictions: Dr. White is subject to non-competition and non-solicitation provisions during and after his employment.
Investor Verification Checklist
- Verify the identity of the registrant as Xenomics, Inc., noting the discrepancy with the requested company name (Cardiff Oncology, Inc.).
- Confirm the status of the definitive employment agreement currently under negotiation.
- Monitor the company's stock price relative to the $9.25 threshold for potential option acceleration.
- Review the attached Exhibit 99.1 (Letter Agreement) for full legal terms.